An edaravone eutectic and its preparation method
By forming a eutectic of edaravone and saccharin, and utilizing hydrogen bonding and solvent-assisted grinding methods, the problem of poor water solubility of edaravone was solved, achieving significant solubilization and crystal morphology stability, making it suitable for industrial production.
Patent Information
- Application Number
- CN202611332572.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-31
- Publication Date
- 2026-11-17
AI Technical Summary
Edaravone has poor water solubility, resulting in low bioavailability. Existing solubilization technologies have limitations, and the eutectic dissolution behavior is complex with a lack of systematic methods for crystal habit regulation, which affects its clinical application.
By forming a eutectic with saccharin, utilizing the sulfonamide groups in the saccharin molecule to form hydrogen bonds with the edaravone molecule, and combining solvent-assisted grinding and cooling crystallization methods, the crystal habit is controlled to form a stable edaravone-saccharin eutectic.
It significantly improves the water solubility of edaravone, has a remarkable solubilizing effect, a simple preparation process, is safe and environmentally friendly, suitable for industrial production, has a stable crystal morphology, and enhances the drug's dissolution rate and formulation stability.
Smart Images

Figure CN123106540A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of eutectic technology, specifically relating to an edaravone eutectic and its preparation method. Background Technology
[0002] Edaravone (chemical name: 3-methyl-1-phenyl-2-pyrazolin-5-one, molecular formula C) 10 H 10 N2O (molecular weight 174.19) is a novel free radical scavenger that was first marketed in Japan in April 2001. Clinically, it is mainly used to treat acute ischemic stroke and has a significant neuroprotective effect.
[0003] A pharmaceutical cocrystal is a crystalline substance formed within the same crystal lattice by two or more different molecular and / or ionic compounds (usually the active pharmaceutical ingredient (API) and the cocrystal form (CCF)) bonded in a fixed stoichiometric ratio through nonionic or noncovalent bonds. The formation of a pharmaceutical cocrystal is essentially a supramolecular self-assembly process, a result of the balance between kinetics, thermodynamics, and molecular recognition. The formation of the supramolecular network in the cocrystal system is influenced by steric effects and intermolecular interactions (hydrogen bonds, π-π stacking, van der Waals forces, halogen bonds, etc.). Hydrogen bonds are the most influential supramolecular force in cocrystal formation; common hydrogen bond synthons include carboxylic acid-pyridine, carboxylic acid-carboxylic acid, carboxylic acid-amide, amide-amide, and alcohol-amine.
[0004] Edaravone faces the following core deficiencies in formulation development and clinical application: (1) Poor water solubility and limited bioavailability: Edaravone has a solubility of about 3 g / L in water (20℃) and an equilibrium solubility of about 3.018 mg / mL in artificial gastric fluid, classifying it as a poorly soluble drug (BCS Class II). Poor water solubility directly limits the development of its oral formulations, resulting in the current clinical practice of mainly administering it via intravenous injection, which is inconvenient for patients and leads to poor compliance.
[0005] (2) Existing solubilization techniques have obvious limitations: The main methods to improve the poor water solubility of edaravone include the preparation of cyclodextrin inclusion complexes, liposomes, and nanoparticles. However, these methods all have different degrees of defects: cyclodextrin inclusion complexes have limited drug loading capacity and complex preparation processes; liposomes have poor stability and high production costs; organic solvents are required in the preparation of nanoparticles, which poses safety risks; although the above methods have all changed the molecular structure of the drug or introduced additional excipients to a certain extent, they may affect the safety and efficacy of the drug.
[0006] (3) The mechanism of solvent-assisted grinding for preparing eutectic is unclear: The mechanism of preparing drug eutectic by mechanochemical method (solvent-assisted grinding) is not fully clear. In particular, the differences in the promoting effect of solvents with different properties (functional group type, dipole moment and polarity, etc.) on the eutectic formation process during solvent-assisted grinding lack systematic research, resulting in a lack of theoretical basis for the selection of preparation process parameters, low preparation efficiency and poor reproducibility.
[0007] (4) The cocrystal dissolution behavior is complex and has a “spring-parachute” effect: When the cocrystal dissolves in an aqueous solvent, its solubility is much higher than that of the active pharmaceutical ingredient, and it will transform into a thermodynamically stable crystalline form of the drug. This causes the drug to precipitate in the solution system, and the drug concentration in the solution drops sharply, which greatly reduces the actual solubility advantage of the cocrystal relative to the drug in the solvent and affects its clinical application effect.
[0008] (5) Lack of systematic methods for controlling the crystal habit of drug cocrystals: The control of the crystal habit of drug cocrystals in solvent systems is still in the stage of empirical exploration and blind trial and error, resulting in high experimental costs and low efficiency. Crystal habit (crystal appearance morphology) directly affects the dissolution rate, flowability, compressibility and formulation stability of drugs. Poor crystal habit (such as needle-shaped crystals) can cause problems such as blockage and agglomeration in the formulation process, which seriously affects the quality of the formulation. Summary of the Invention
[0009] The purpose of this invention is to provide an edaravone eutectic and its preparation method, which increases the water solubility of edaravone by 3 to 4 times (283.15 to 323.15 K) without changing the molecular structure and pharmacological activity of edaravone.
[0010] This invention first provides an edaravone cocrystal, comprising edaravone and saccharin, wherein the saccharin molecule contains a sulfonylimide group, and its carbonyl oxygen and sulfonyl oxygen act as hydrogen bond acceptors, interacting with the NH of the pyrazolone structure and the OH of the enol structure in the edaravone molecule through hydrogen bond interaction; at the same time, the saccharin molecule retains its own NH···O=C cyclic dimer, which synergistically constructs a directional hydrogen bond network and a three-dimensional lattice. The PXRD pattern of the cocrystal has a characteristic diffraction peak at 2θ=18.9°.
[0011] This invention also provides a method for preparing edaravone eutectic, comprising: Edaravone and saccharin were placed in a grinder, a solvent was added, and the mixture was ground and dried to obtain edaravone eutectic.
[0012] Preferably, the molar ratio of edaravone to saccharin is (1-2):(1-2).
[0013] Preferably, the molar ratio of edaravone to saccharin is 1:1.
[0014] Preferably, the solvent is ethanol, methanol, isopropanol or ethyl acetate.
[0015] Preferably, the solvent amount is expressed as volume / solid mass. η represents, η The range is 0.00185 ~ 0.00463 μL / mg.
[0016] Preferably, the grinding time is 60-90 minutes.
[0017] The present invention also provides a method for controlling the crystal habit of edaravone-saccharin cocrystal. The above-mentioned edaravone cocrystal is added to a reactor in ethanol or isopropanol solvent, and cooled to 278.15 K at a cooling rate of 0.1 K / min from 333.15 K or 323.15 K for cooling crystallization. After crystallization for 2 h, the crystals are filtered and dried to obtain blocky edaravone-saccharin cocrystal.
[0018] Preferably, anionic surfactants can also be added during the cooling process.
[0019] Preferably, the concentration of the anionic surfactant SDS or SDBS is 0.02 mol / L.
[0020] Beneficial effects of the present invention (1) Significant solubilizing effect: The solubility of edaravone-saccharin cocrystal in water, methanol, ethanol, isopropanol and acetone is about 3 to 4 times that of the raw drug, and the solubilizing effect is significant.
[0021] (2) Without altering the drug structure, the cocrystallization technique combines edaravone with saccharin through non-covalent bonds (hydrogen bonds). The saccharin molecule contains a sulfonylimide group (-SO2NH-), and its carbonyl O and sulfonyl O can act as hydrogen bond acceptors, forming strong hydrogen bonds (NH···O=C, OH···O=S) with the pyrazolone NH (hydrogen bond donor) and enol OH (hydrogen bond donor) in the edaravone molecule. At the same time, saccharin retains its own NH···O=C cyclic dimer, jointly constructing a directional hydrogen bond network and a three-dimensional lattice, without altering the molecular structure and pharmacological activity of edaravone, providing a good molecular recognition basis for the formation of a stable cocrystallization.
[0022] (3) The preparation process is simple, and the solvent-assisted grinding method is easy to operate, requiring only a small amount of solvent ( η (≤ 1 μL / mg), requires no high temperature or high pressure, is green and environmentally friendly, and is suitable for industrial-scale production.
[0023] (4) The eutectic formation is safe. Saccharin (CAS: 81-07-2) is an FDA-approved food additive that is physiologically acceptable, has high safety, and meets the requirements for pharmaceutical excipients. Attached Figure Description
[0024] Figure 1 The PXRD spectra of the products obtained by grinding the physical mixture of edaravone and saccharin solids of the present invention for different times with ethanol solvent-assisted grinding. Figure 2 PXRD spectra of products obtained by grinding a physical mixture of edaravone and saccharin raw materials with different solvents; Figure 3 This is a schematic diagram illustrating the mechanism of the eutectic formation process of edaravone and saccharin molecules through dissolution-assisted grinding. Figure 4 Scatter plot of the solubility of edaravone-saccharin eutectic in five single solvents; Figure 5 A comparison chart of the solubility of edaravone-saccharin eutectic and edaravone active pharmaceutical ingredient in water; Figure 6 SEM image of crystals obtained by cooling and crystallizing edaravone-saccharin eutectic in ethanol; Figure 7 SEM image of the crystals obtained by cooling and crystallizing edaravone-saccharin eutectic in isopropanol; Figure 8 SEM images of crystals obtained by cooling and crystallizing edaravone-saccharin eutectic in ethanol at temperatures ranging from 333.15 to 278.15 K; Figure 9 SEM images of crystals obtained by cooling and crystallizing edaravone-saccharin eutectic in solutions of different additives at temperatures ranging from 323.15 to 278.1 degrees Celsius. Figure 10 SEM images of crystals obtained by cooling and crystallizing edaravone-saccharin eutectic in ethanol solutions containing different additives at temperatures ranging from 323.15 to 278.15 K. Figure 11 The PXRD spectra of edaravone-saccharin eutectic crystals obtained by cooling and crystallizing in ethanol and solutions containing different additives at temperatures ranging from 323.15 to 278.15 K. Detailed Implementation
[0025] This invention first presents an edaravone cocrystal, comprising edaravone and saccharin. The saccharin molecule contains a sulfonylimide group, whose carbonyl oxygen and sulfonyl oxygen act as hydrogen bond acceptors, interacting with the NH₃ of the pyrazolone structure and the OH₃ of the enol structure in the edaravone molecule through hydrogen bond interactions. Simultaneously, the saccharin molecule retains its own NH···O=C cyclic dimer, synergistically constructing a directional hydrogen bond network and a three-dimensional lattice. The PXRD characteristic peak is located at 2θ = 18.9°. The mechanism of the cocrystal formation process of edaravone and saccharin molecules through dissolution-assisted grinding is shown in the diagram below. Figure 3 As shown.
[0026] This invention also provides a method for preparing edaravone eutectic, comprising: Edaravone and saccharin are placed in a grinder, a solvent is added, and the mixture is ground and dried to obtain an edaravone eutectic. The preferred molar ratio of edaravone to saccharin is 1:1.
[0027] According to the present invention, the solvent is preferably ethanol, methanol, isopropanol, or ethyl acetate, more preferably ethanol, methanol, or isopropanol. The solvent amount is expressed as volume / solid mass. η represents, η The range is 0.00185 ~ 0.00463 μL / m (i.e., 2 ~ 10 μL of solvent added per gram of solid). When η When the concentration is ≥ 0.00185 μL / mg, the grinding product is a pure eutectic. η The larger the value, the higher the eutectic content.
[0028] According to the present invention, the preferred grinding time is 60-90 minutes. During the grinding process, mechanical force provides energy for the formation of hydrogen bonds between edaravone molecules and saccharin molecules, and a small amount of solvent acts as a "catalyst," accelerating molecular diffusion and eutectic formation. Grinding for 60 minutes can completely transform the physical mixture into a eutectic; grinding for 90 minutes can further improve the crystallinity of the eutectic.
[0029] According to the present invention, after grinding, the solid obtained by grinding is placed in a vacuum drying oven to dry and remove residual solvent, thereby obtaining an edaravone-saccharin eutectic product.
[0030] The present invention also provides a method for controlling the crystal habit of edaravone-saccharin cocrystal. The above-mentioned edaravone cocrystal is added to a reactor in ethanol or isopropanol solvent, and cooled to 278.15 K at a cooling rate of 0.1 K / min from 333.15 K or 323.15 K for cooling crystallization. After crystallization for 2 h, the crystals are filtered and dried to obtain blocky edaravone-saccharin cocrystal.
[0031] According to the present invention, an anionic surfactant can also be added during the cooling process. The anionic surfactant is preferably SDS or SDBS at a concentration of 0.02 mol / L. Adding the anionic surfactant can further increase the crystal bulk density and maintain the bulk crystal habit.
[0032] The present invention will be further described in detail below with reference to specific embodiments. The reagents used in this experiment are as follows: edaravone (≥99.5%, CAS: 89-25-8), saccharin (≥99.5%, Saccharin, chemical name: 1,2-benzisothiazol-3(2H)-one-1,1-dioxide, CAS: 81-07-2, molecular formula C7H5NO3S, molecular weight 183.18) were purchased from Shanghai Maclean Biochemical Co., Ltd.; ethanol (≥99.8%, CAS: 64-17-5), methanol (≥99.7%, CAS: 67-56-1), isopropanol (≥99.7%, CAS: 67-63-0), ethyl acetate (≥99.5%, CAS: 141-78-6), and acetone (≥99.5%, CAS: 67-64-1) used only as a control were all purchased from Liaoning Quanrui Chemical Co., Ltd. Instruments: Analytical balance, model AB204-N (accuracy 0.0001g), powder X-ray diffractometer, model D / MAX 2500 (Cu-Kα, λ=1.54056 Å).
[0033] Example 1 i. Weighing raw materials: Weigh 1.052 g of edaravone (about 6.04 mmol, molecular weight 174.19) and 1.106 g of saccharin (about 6.04 mmol, molecular weight 183.18) in a molar ratio of 1:1, mix them evenly, and place them in an agate mortar.
[0034] ii. Add grinding aid solvent: Add methanol solvent to the mixture using a micro-syringe. η It is 0.00185 μ L / mg.
[0035] iii. Manual grinding: Place the mixture in an agate mortar and grind manually for 60 minutes. iv. Drying: After grinding, place the resulting solid in a vacuum drying oven to remove residual solvent and obtain the edaravone-saccharin eutectic product.
[0036] v. Product Characterization: The dried sample was analyzed using a powder X-ray diffractometer (PXRD) at a resolution of 2... θ The diffraction peak at 18.9° was taken as the characteristic peak of the edaravone-saccharin eutectic, confirming the formation of the eutectic. The characteristic peak of the eutectic is similar to that of the edaravone raw material (characteristic peak: 2...). θ = 11.2°) and saccharin raw material (characteristic peak: 2 θ The characteristic peaks of the two (= 12.4°) are different, and the PXRD spectrum of the physical mixture is a superposition of the two, with no new characteristic peaks appearing.
[0037] Example 2 The method and steps are the same as in Example 1, except that ethanol is used as the solvent. The ethanol-assisted grinding process is different. η The peak intensity fractions of the products obtained under the given conditions are shown in Table 1: Table 1. Differences in Ethanol-Assisted Grinding η Peak intensity fraction of the product obtained under the conditions
[0038] a when η When the value is ≥0.00185, the grinding product is a pure eutectic. Example 3 The method and steps are the same as in Example 1, except that isopropanol is used as the solvent.
[0039] Example 4 The method and steps are the same as in Example 1, except that ethyl acetate is used as the solvent. The grinding process assisted by ethyl acetate is different. η The peak intensity fractions of the products obtained under the given conditions are shown in Table 2: Table 2 Differences in Ethyl Acetate-Assisted Grinding η Peak intensity fraction of the product obtained under the conditions
[0040] a when η When the value is ≥0.00185, the grinding product is a pure eutectic. Comparative Example 1 The method and steps are the same as in Example 1, except that acetone is used as the solvent.
[0041] Examples 1-4 and Comparative Example 1 investigated the effect of solvent properties on the eutectic formation process using different solvents. Figure 2 The PXRD spectra of the products obtained by grinding a physical mixture of edaravone and saccharin raw materials with different solvents show that: Solvent polarity: Except for ethyl acetate, the eutectic content of the grinding products is related to solvent polarity (expressed as a polarity parameter). E T (30) Characterization) is directly proportional, that is, methanol ( E T (30) = 55.4) > Ethanol (51.9) > Isopropanol (48.4). The stronger the polarity of the solvent, the stronger its effect on the diffusion of raw material molecules, and the faster the eutectic formation rate.
[0042] Functional group effect: The hydroxyl groups in alcohol solvent molecules can form hydrogen bonds with the raw material molecules, producing a "solvent occupancy effect" that slows down the eutectic formation rate. Although ethyl acetate is less polar than isopropanol, it does not have hydroxyl groups and therefore does not experience the occupancy effect; thus, its effect on promoting eutectic formation is better than that of isopropanol. Therefore, the promoting effect of solvents on eutectic formation is the result of the combined effect of polarity and functional groups.
[0043] In addition, as can be seen from Comparative Example 1, acetone is not suitable for solvent-assisted grinding preparation of edaravone-saccharin eutectic. The product after acetone-assisted grinding is a yellow paste, and PXRD analysis shows that it is an amorphous substance and cannot form a crystalline eutectic product.
[0044] Example 5 The method and steps are the same as in Example 1, except that the solvent is ethanol and the grinding time is changed to 90 min.
[0045] Comparative Example 2 The method and steps are the same as in Example 1, except that the solvent is ethanol and the grinding time is modified to 20 min and 30 min, respectively. Figure 1 The figure shows the PXRD spectra of the products obtained by ethanol solvent-assisted grinding of a physical mixture of edaravone and saccharin solids at different times. It can be seen that after 20 min of solvent-assisted grinding, the characteristic peak intensities of the ground product at 2θ = 11.2°, 13.6°, and 12.4° are weaker than those of the physical mixture of edaravone and saccharin, and a new characteristic peak is generated at 2θ = 20.3°. This indicates that the edaravone and saccharin solid powders have begun, but not completely, to transform into a eutectic after 20 min of ethanol solvent-assisted grinding. After 30 min of ethanol solvent-assisted grinding, the characteristic peaks at 2θ = 11.2°, 12.4°, and 13.6° further weaken, indicating that after 30 min of ethanol solvent-assisted grinding, the physical mixture of edaravone and saccharin raw materials further transforms into a eutectic, but is still not completely transformed.
[0046] Determination of the solubility of edaravone-saccharin eutectic This invention employs a static weighing method to systematically determine the solubility of edaravone raw material and edaravone-saccharin cocrystal in solvents such as water, methanol, ethanol, isopropanol, and acetone, within a temperature range of 283.15 ~ 323.15 K.
[0047] 1. Set the temperature: Fix the jacketed reactor on the iron stand and connect it to the circulating water bath. Turn on the circulating water bath and set the temperature to the initial experimental temperature (283.15 K) with an accuracy of ± 0.01 K.
[0048] 2. Filling materials: Weigh a certain amount of solvent using a graduated cylinder and inject it into the jacketed reactor. Turn on the magnetic stirrer and weigh a certain amount of solute using an analytical balance (accuracy 0.0001 g). Add the solid to the reactor in batches according to the state of the suspension until the state of the solid suspension does not change significantly within 10 minutes. The system is considered to have reached solid-liquid phase equilibrium.
[0049] 3. Stirring and equilibration: The entire solution system is continuously stirred at the set temperature for no less than the optimal equilibrium time to ensure that the solute and solvent are in full contact and reach solid-liquid phase equilibrium.
[0050] 4. Sedimentation separation: Stop stirring and allow the system to settle at the measured temperature for at least 30 minutes until no fine solute particles are observed in the upper layer of the solution, thus achieving complete separation of the solid and liquid phases.
[0051] 5. Sampling and filtration: Place the empty petri dish on the balance pan and record its mass. Take out the preheated (about 60°C) syringe, install the filter with a 0.45 μm pore size filter membrane, draw 3-5 mL of saturated solution and quickly inject it into the empty petri dish, and record the balance reading.
[0052] 6. Drying and Weighing: Place the petri dish containing the saturated solution in a 60℃ constant temperature vacuum drying oven for approximately 24 hours to ensure complete solvent evaporation. After cooling to room temperature, weigh the dish. Repeat this process until there is no significant decrease in mass. Record the final mass and calculate the solubility.
[0053] 7. Temperature measurement: Adjust the water bath temperature to the next experimental temperature point. If the solid dissolves, add more solute. Repeat steps 3 to 6 to measure the solubility at each temperature point in sequence.
[0054] Figure 4 This is a scatter plot of the solubility of edaravone-saccharin eutectic in five single solvents. Figure 5 The graph compares the solubility of edaravone-saccharin cocrystal and edaravone active pharmaceutical ingredient (API) in water. Within the temperature range of 283.15–323.15 K, the solubility of the edaravone-saccharin cocrystal in all five solvents increases monotonically with increasing temperature. Specifically, at a constant temperature, the solubility of the cocrystal in pure water is approximately 3–4 times that of the API, and the solubility of the cocrystal is more sensitive to temperature changes. The solubility of the cocrystal in each solvent, from highest to lowest, is: acetone > methanol > ethanol > isopropanol > water, consistent with the solubility pattern of the API, indicating that the introduction of saccharin did not alter the solvation effect of edaravone.
[0055] Example 6: Method for controlling the crystal habit of edaravone-saccharin eutectic ① Cooling crystallization method i. Prepare the solution: Pour ethanol or isopropanol into a 100 mL jacketed reactor, connect a programmable temperature-controlled constant temperature water bath, and set the magnetic stirring speed to 300 rpm.
[0056] ii Dissolving the eutectic: Add a certain amount of edaravone-saccharin eutectic to the reactor, turn on magnetic stirring at 333.15 K (or 323.15 K) to fully dissolve the eutectic, and maintain a constant stirring rate for 1 h to ensure that the solid is completely dissolved.
[0057] iii. Programmed cooling: Cool the solution system to 278.15 K at a cooling rate of 0.1 K / min.
[0058] iv. Crystal growth and filtration: Maintain a constant water bath temperature and allow the entire system to stand for 2 hours for crystal growth before filtration. The crystals are then removed using silica gel desiccant (RH = 0%). T Dry at 293.15 K for 24 h.
[0059] v Crystal characterization: Crystals obtained under different solvent and temperature conditions were collected and characterized by scanning electron microscopy (SEM) to observe crystal morphology and aspect ratio.
[0060] Figure 6 The crystal habit of edaravone-saccharin eutectic crystals obtained by cooling and crystallizing in ethanol at a temperature range of 323.15 - 278.15 K is shown. It can be seen that the crystal habit of edaravone-saccharin eutectic crystals obtained by cooling and crystallizing in ethanol is blocky, and the inter-crystal voids are relatively large.
[0061] Figure 7 The crystal habit of edaravone-saccharin eutectic crystals obtained by cooling and crystallizing in isopropanol at a temperature ranging from 323.15 to 278.15 K is shown. It can be seen that the crystal habit of edaravone-saccharin eutectic crystals obtained by cooling and crystallizing in isopropanol is also blocky, with relatively large inter-crystal gaps. Furthermore, the crystals obtained in isopropanol are significantly larger than those obtained in ethanol.
[0062] Figure 8 The crystal habit of edaravone-saccharin eutectic obtained by cooling crystallization in ethanol at a temperature range of 333.15 - 278.15 K is shown; it can be seen that the crystal morphology is different from that obtained by cooling crystallization at a temperature range of 323.15 - 278.15 K. Figure 6 Compared to edaravone-saccharin eutectic, the crystals obtained by cooling and crystallizing at 333.15 - 278.15 K are larger and have a lower bulk density.
[0063] ② Additives regulate crystal habit This invention systematically studied the regulatory effects of three surfactants on the crystal habit of edaravone-saccharin co-crystals. The specific additives were added after the temperature reduction procedure in step iii, as shown in Table 3 below: Table 3
[0064] Figure 10 SEM images of edaravone-saccharin eutectic crystals obtained by cooling and crystallizing in ethanol solutions containing different additives at temperatures ranging from 323.15 to 278.15 K (a is SDS, b is SDBS, c is Tween 80). Figure 11 The PXRD spectra of edaravone-saccharin eutectic crystals obtained by cooling and crystallizing in ethanol and solutions containing different additives at temperatures ranging from 323.15 to 278.15 K.
[0065] It can be seen that the anionic surfactants SDS and SDBS preferentially adsorb onto the {100} dominant crystal plane through the synergistic effect of electrostatic attraction and hydrogen bonding, selectively inhibiting the growth of this crystal plane, maintaining the bulk crystal habit, and the bulk density is better than that of the cooled crystallized product in pure solvent; the nonionic surfactant Tween 80 has a weaker ability to regulate the crystal habit than the ionic surfactant, causing the crystal aspect ratio to increase and tend to be rod-shaped; none of the three additives change the eutectic crystal form.
[0066] The additives used in this invention are all surfactants, and the properties of surfactants are closely related to their critical micelle concentration (CMC). When the concentration of surfactants in a solution reaches a certain value, their molecules polymerize from monomers into colloidal polymers, forming micelles; this process is called micellization. The minimum concentration of surfactant required to form micelles is called the micelle concentration (CMC). Generally, the lower the CMC value, the higher the efficiency of the surfactant. Surfactants can only exert their full effect when the concentration is slightly higher than their critical micelle concentration. Literature review shows that the CMCs of sodium dodecyl sulfate (SDS) and sodium dodecylbenzene sulfonate (SDBS) are 0.0080 mol / L (298.15 K) and 0.0086 mol / L (313.15 K), respectively. To investigate whether the effect of additives on the crystal habit of edaravone-saccharin eutectic is related to the CMC value, a certain amount of eutectic was first dissolved in 0.02 mol / L SDS and SDBS solutions, respectively, and then cooled for crystallization (temperature range 323.15 - 278.15 K). SEM images of the resulting crystals are shown below. Figure 9 As shown, where Figure 9 'a' represents SDS. Figure 9b represents SDBS. As shown in the figure, even when the concentrations of both SDS and SDBS are greater than their respective CMC values, the edaravone-saccharin eutectic still grows into a bulk crystal. Therefore, the effect of surfactants on the crystal habit of the edaravone-saccharin eutectic is almost independent of its critical micelle concentration. The fact that the eutectic still grows into a bulk crystal even when the concentrations of both SDS and SDBS are greater than their respective CMC values indicates that the effect of surfactants on the crystal habit depends primarily on their selective interaction with the crystal planes, rather than micellarization behavior.
[0067] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
[0068] Furthermore, those skilled in the art will understand that although some embodiments herein include certain features included in other embodiments but not others, combinations of features from different embodiments are meant to be within the scope of the invention and form different embodiments. For example, in the foregoing claims, any of the claimed embodiments can be used in any combination. The information disclosed in this background section is intended only to enhance the understanding of the general background of the invention and should not be construed as an admission or in any way implying that such information constitutes prior art known to those skilled in the art.
Claims
1. An edaravone eutectic, characterized in that, The saccharin molecule contains a sulfonyl imide group, where the carbonyl oxygen and sulfonyl oxygen act as hydrogen bond acceptors, interacting with the NH group of the pyrazolone structure and the OH group of the enol structure in the edaravone molecule through hydrogen bond interaction. At the same time, the saccharin molecule retains its own NH···O=C cyclic dimer, which together constructs a directional hydrogen bond network and a three-dimensional lattice. The PXRD pattern of the eutectic has a characteristic diffraction peak at 2θ=18.9°.
2. The method for preparing an edaravone eutectic according to claim 1, characterized in that, include: Edaravone and saccharin were placed in a grinder, a solvent was added, and the mixture was ground and dried to obtain edaravone eutectic.
3. The method for preparing an edaravone eutectic according to claim 2, characterized in that, The molar ratio of edaravone to saccharin is (1-2):(1-2).
4. The method for preparing an edaravone eutectic according to claim 3, characterized in that, The molar ratio of edaravone to saccharin is 1:
1.
5. The method for preparing an edaravone eutectic according to claim 2, characterized in that, The solvent is ethanol, methanol, isopropanol or ethyl acetate.
6. The method for preparing an edaravone eutectic according to claim 2, characterized in that, The solvent amount is expressed as volume / solid mass. η represents, η The range is 0.00185 ~ 0.00463 μL / mg.
7. The method for preparing an edaravone eutectic according to claim 2, characterized in that, The grinding time is 60-90 minutes.
8. A method for controlling the crystal habit of edaravone-saccharin eutectic, characterized in that, The above-mentioned edaravone eutectic was added to the reactor in ethanol or isopropanol solvent, and cooled to 278.15 K at a cooling rate of 0.1 K / min from 333.15 K or 323.15 K for cooling crystallization. After crystallization for 2 h, the crystals were filtered and dried to obtain blocky edaravone-saccharin eutectic.
9. The method for controlling the crystal habit of edaravone-saccharin eutectic according to claim 8, characterized in that, Anionic surfactants can also be added during the cooling process.
10. The method for controlling the crystal habit of edaravone-saccharin eutectic according to claim 9, characterized in that, The anionic surfactant SDS or SDBS has a concentration of 0.02 mol / L.
